News

The researchers found that from 2010 to 2023, there was an increase in the percentage of the T1D population prescribed GLP-1 RAs from 0.3 to 6.6%, while SGLT2 inhibitor prescribing increased from ...
No blanket recommendation can be made for SGLT2 inhibitors and GLP-1 receptor agonists in adults with type 2 diabetes (T2D) ...
They compared patients prescribed GLP-1-RAs or SGLT2 inhibitors with 68,400 patients prescribed DPP-4 inhibitors, which previous studies suggest do not increase ARD risk.
SGLT-2 inhibitor and GLP-1 receptor agonist drugs should be used in all or almost all adults with type 2 diabetes at higher ...
Compared with the general type 1 diabetes population, those newly prescribed a GLP-1 agonist or SGLT2 inhibitor tended to be older (41.5 vs 47.1 vs 56.8 years, respectively).
Of those who were not using SGLT2 inhibitors at baseline, 290 of 1490 (19.5%) treated with semaglutide vs 372 of 1493 (24.9%) receiving placebo had the kidney composite outcome (HR, 0.73; P < .001).
GLP-1 receptor agonists may reduce cancer risk among people with obesity or overweight, according to retrospective study results.Adults who used GLP-1 medications exhibited a statistically significant ...
Within the subclass of GLP-1 RAs, semaglutide increased the most, from 0.2% to 4.4% from 2018 to 2023. Within 1 year, tirzepatide, which was approved in 2022, reached 1.3%.
GLP-1 RAs, SGLT2 Inhibitors May Reduce Risk for Alzheimer Disease, Dementia in T2DM April 18, 2025 ...
Investigators also pointed out SGLT2 inhibitors had a greater proportion of users with any albuminuria (31.3% or heart failure (6.3% vs 0%) than GLP-1 receptor agonist users.
Fewer than one in 10 adults with type 2 diabetes in the U.S. use SGLT2 inhibitors or GLP-1 receptor agonists, and only SGLT2 inhibitors have seen an increase in use over the last decade, according ...
GLP-1 receptor (GLP-1R) agonists and DPP-4 inhibitors increase natriuresis in T2DM, possibly through overlapping and distinct mechanisms, and might slightly improve renal haemodynamics in the ...